Sun Pharma Dismisses $10 Billion Organon Acquisition Report as 'Speculative'

• Sun Pharma stated that reports of its $10 billion acquisition of US drugmaker Organon are "speculative" and lack material disclosure events.
• The Economic Times reported Sun Pharma is evaluating a takeover of Organon, potentially the largest overseas acquisition by an Indian drugmaker.
• The deal could strengthen Sun Pharma's US commercial base, expand its presence in women's health, and boost its biosimilars segment.
• Organon, spun off from Merck in 2021 with significant debt, has seen its market value halve, attracting buyer interest.
• Sun Pharma has engaged a European bank for financing, but the outcome of discussions remains uncertain, with rival interest possible.

Why It Matters: Sun Pharma denies reports of a $10 billion Organon acquisition, calling them speculative despite market speculation.